Literature DB >> 21591465

[Lung cancer in Japan: analysis of lung cancer registry cases resected in 2004].

Noriyoshi Sawabata1, Yoshitaka Fujii, Hisao Asamura, Hiroaki Nomori, Yoichi Nakanishi, Kenji Eguchi, Masaki Mori, Meinoshin Okumura, Etsuo Miyaoka, Kohei Yokoi.   

Abstract

The Japan Lung Cancer Society, Japanese Association for Chest Surgery, and Japanese Respiratory Society jointly established the Japanese Joint Committee for Lung Cancer Registration. In 2010, analyses of 11,663 cases of lung cancer that underwent surgical resection in 2004 were performed, then the findings were registered and collected for analysis by the committee. The survival rate for all cases was 69.6%, while the 5-year survival rate in males (n = 7.369) was 63.0% and 80.9% in females (n = 4,294). The 5-year survival rates by c-stage (UICC Ver. 6 and Ver. 7) were as follow: IA (n = 6,295, 6,295), 82.0% and 82.0%; IB (n = 2,788, 2,339), 63.4% and 66.1%, IIA (n = 203, 819), 55.4% and 54.5%; IIB (n = 899, 648), 48.6% and 46.4%: IIIA (n = 940, 1,216), 43.3% and 42.8%; IIIB (n = 407, 90), 41.6% and 40.3% and IV (n = 131, 256), 29.1% and 31.4%, respectively. The 5-year survival rates by p-stage (UICC Ver. 6 and Ver. 7) were as follow: IA (n = 5,611, 4,978), 85.9% and 86.8%; IB (n = 2,398, 2,552), 69.3% and 73.9%; IIA (n = 336, 941), 60.9% and 61.6%; IIB (n = 977, 848), 51.1% and 49.8%; IIIA (n = 1354, 1804), 41.0% and 40.9%; IIIB (n = 799, 106), 36.7% and 27.8%, and IV (n = 188, 434), 27.8% and 27.9%, respectively. The 5-year survival rates by histological type were as follow: adenocarcinoma, 74.9% squamous cell carcinoma, 59.1%; large cell carcinoma, 53.3% small cell carcinoma, 52.6%; and adenosquamous cell carcinoma, 50.8%. Operative death occurred in 48 cases (0.4%) and hospital death in 46 (0.4%).

Entities:  

Mesh:

Year:  2011        PMID: 21591465

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  8 in total

1.  Lung cancers unrelated to smoking: characterized by single oncogene addiction?

Authors:  Kenichi Suda; Kenji Tomizawa; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  Int J Clin Oncol       Date:  2011-06-08       Impact factor: 3.402

Review 2.  Surgical management of locally advanced lung cancer.

Authors:  Kohei Yokoi; Tetsuo Taniguchi; Noriyasu Usami; Koji Kawaguchi; Takayuki Fukui; Futoshi Ishiguro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-05-29

3.  Management of acute ischemic stroke after pulmonary resection: incidence and efficacy of endovascular thrombus aspiration.

Authors:  Daisuke Kimura; Ikuo Fukuda; Takao Tsushima; Takehiro Sakai; Satoko Umetsu; Yukari Ogasawara; Norihito Shimamura; Hiroki Ohkuma
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-10-26

4.  Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma.

Authors:  Gouji Toyokawa; Yuka Kozuma; Taichi Matsubara; Naoki Haratake; Shinkichi Takamori; Takaki Akamine; Kazuki Takada; Masakazu Katsura; Mototsugu Shimokawa; Fumihiro Shoji; Tatsuro Okamoto; Yoshihiko Maehara
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

5.  Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.

Authors:  Hirokazu Urushiyama; Taisuke Jo; Hideo Yasunaga; Nobuaki Michihata; Hiroki Matsui; Wakae Hasegawa; Hideyuki Takeshima; Yukiyo Sakamoto; Yoshihisa Hiraishi; Akihisa Mitani; Kiyohide Fushimi; Takahide Nagase; Yasuhiro Yamauchi
Journal:  Cancer Med       Date:  2018-08-27       Impact factor: 4.452

6.  Survival analyses of postoperative lung cancer patients: an investigation using Japanese administrative data.

Authors:  Susumu Kunisawa; Kazuto Yamashita; Hiroshi Ikai; Tetsuya Otsubo; Yuichi Imanaka
Journal:  Springerplus       Date:  2014-05-01

7.  Surgery for non-small cell lung cancer in patients with a history of cardiovascular surgery.

Authors:  Hideyuki Maeda; Masato Kanzaki; Kei Sakamoto; Tamami Isaka; Kenji Yamazaki; Takamasa Onuki
Journal:  Surg Today       Date:  2016-07-21       Impact factor: 2.549

8.  Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.

Authors:  Yoshinobu Hata; Takaharu Kiribayashi; Kazuma Kishi; Makoto Nagashima; Takefumi Nakayama; Shingo Ikeda; Mitsutaka Kadokura; Yuichi Ozeki; Hajime Otsuka; Yoshitaka Murakami; Keigo Takagi; Akira Iyoda
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.